BIOLOG-ID
6.7.2021 17:05:10 CEST | Business Wire | Press release
Biolog-id, a global service provider of connected healthcare solutions, and Inlog , a software company dedicated to the medical sector, have announced today a strategic interoperability partnership for their solutions.
With a market presence of more than 30 years, Inlog has developed software suites that ensure the quality and the traceability of products throughout the transfusion supply chain. These software suites are used today by nearly 250 French and international clients, including an important part of University Hospitals.
To allow blood centers and hospitals to take advantage of the RFID technology, Inlog and biolog-id are partnering to guarantee the interoperability of the Edge Track (Hemo Server) and Edge Blood (CTS Server) software with the Biolog Data System modules from the Biolog Transfusion Solution.
By combining RFID tags containing essential information of blood products, connected equipment, and a dedicated transactional and decision-making software, Biolog Transfusion Solution secures the entire blood transfusion supply chain, from the donor to the recipient. Beyond reinforcing the safety of transfused patients, the solution optimizes in real-time the local and remote inventory management of these vital therapeutic products and allows them to be attributed nominatively remotely and safely.
“We are very pleased that Inlog, who is today a reference in the field of blood supply chain management, and biolog-id collaborate to propose their users and prospects an option for strengthening traceability and securing the transfusion chain based on our RFID solution”, says Bruno Chappert, CEO at biolog-id. “This interoperability agreement will enable us to offer transfusion professionals a new feature capable of improving their efficiency, optimizing working conditions while adapting to all types of structures, and finally facilitating the rapid implementation of these software solutions”.
“We are convinced that this interoperability agreement between biolog-id and Inlog will provide healthcare and transfusion facilities with better blood product management, enhanced safety and improved traceability”, underlines David Kalfon, President at Inlog. “The numerous combined advantages of biolog-id and Inlog solutions will allow the transfusion chain professionals to rationalize their operations and optimize their costs”.
The Inlog software and Biolog Transfusion Solution will be available under different technical models to allow simple, fast and modular integration by healthcare infrastructures and to meet users’ needs.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Inlog:
Founded in 1992, Inlog is one of the leading French software companies in the field of medical informatics for laboratory analysis, traceability of blood products in healthcare facilities and the various activities of blood transfusion centers.
Inlog designs and develops a range of software for the healthcare sector whose advantages in terms of robustness, reliability and ease of configuration are distinguished by all its customers. Motivated by a new management board, Inlog is initiating an ambitious project to use new technologies into its applications to make their use even more ergonomic and intuitive.
The Inlog software suites, CE marked, are used by more than 250 Healthcare institutions in France and around the world (Germany, Switzerland, Belgium, Canada, Hong Kong, etc.), including some prestigious partners such as the Etablissement Français du Sang, the Hôpitaux Universitaires Genevois and the Flemish Red Cross.
Inlog is currently supported by the French investment fund Abénex, a major player in private equity in France.
Company URL: https://www.inlog.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom